Paradigm Biocapital Advisors LP Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Paradigm Biocapital Advisors LP purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 400,000 shares of the company's stock, valued at approximately $17,288,000. Scholar Rock accounts for about 0.6% of Paradigm Biocapital Advisors LP's portfolio, making the stock its 26th largest position. Paradigm Biocapital Advisors LP owned about 0.43% of Scholar Rock as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. FMR LLC grew its holdings in shares of Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after purchasing an additional 3,439,215 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after purchasing an additional 2,732,546 shares in the last quarter. Norges Bank acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $86,043,000. Fairmount Funds Management LLC acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $84,839,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $68,930,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Scholar Rock

In other news, insider Tracey Sacco sold 5,000 shares of the company's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the completion of the transaction, the insider now owns 71,750 shares in the company, valued at approximately $2,355,552.50. This represents a 6.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Katie Peng sold 1,006 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the transaction, the director now owns 30,319 shares of the company's stock, valued at approximately $1,043,579.98. The trade was a 3.21% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 255,231 shares of company stock valued at $9,220,236. Insiders own 13.30% of the company's stock.

Scholar Rock Stock Down 0.9%

Shares of NASDAQ:SRRK traded down $0.28 during trading hours on Friday, reaching $30.55. The stock had a trading volume of 1,075,653 shares, compared to its average volume of 1,273,907. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The firm's 50 day moving average is $31.19 and its 200-day moving average is $35.87. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). Research analysts predict that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush restated an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.